- Home
- INMB vs ALGS Comparison
INMB vs ALGS Comparison
Compare INMB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 34.6M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INMB | ALGS |
|---|---|---|
| Price | $2.22 | $5.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $5.40 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 303.1K | 54.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.85 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | $50,000.00 | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $3.98 |
| 52 Week High | $2.60 | $13.69 |
Technical Indicators
Market Signals| Indicator | INMB | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 37.57 |
| Support Level | $1.16 | $4.80 |
| Resistance Level | $2.30 | $6.91 |
| Average True Range (ATR) | 0.13 | 0.52 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 1.25 | 1.16 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.